• Explore /
  • Poster
  • / Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, <em>HER2</em>-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.

Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.

Abstract Poster

Authors

Komal Jhaveri

Komal L. Jhaveri

Memorial Sloan Kettering Cancer Center, New York, NY

Komal L. Jhaveri , Jonathan W. Goldman , Sara A. Hurvitz , Angel Guerrero-Zotano , Nisha Unni , Adam Brufsky , Haeseong Park , James Ross Waisman , Eddy Shih-Hsin Yang , Iben Spanggaard , Sonya A. Reid , Mark E. Burkard , Aleix Prat , Sherene Loi , John Crown , Ariella Hanker , Cynthia X. Ma , Ron Bose , Lisa DeFazio Eli , Hans Wildiers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT01953926

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 1028)

DOI

10.1200/JCO.2022.40.16_suppl.1028

Abstract #

1028

Poster Bd #

406

Abstract Disclosures

Similar Posters

First Author: Kelvin K H Bao

First Author: Rinath Jeselsohn

First Author: Rachel M. Layman

First Author: Cristina I. Truica